CTIS2023-503545-67-00招募中1 期
A Multicenter, Open-Label, Study to Evaluate the Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults with Tourette’s Disorder - EBS-101-TD-391
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 141
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 65+（—）
- 性别
- All
入选标准
- •Subjects enrolling from the EBS-101-TD-301 completed all visits through Week 24 and days 7 and 14 safety follow-up; OR met relapse criteria, as defined in the EBS-101-TD-301 study, during the double-blind R/WD period and have completed the Early Termination visit, Day 7, and Day 14 Follow Up visits. Subjects enrolling from studies EBS-101-OL-001 or PSY302A who completed the respective studies; In the opinion of the Investigator the subject must have had clinical benefit from ecopipam and would benefit from continued participation; Female participants of childbearing potential must agree to use a highly effective method of contraception (i.e., pregnancy rate of less than 1% per year) during the study and for 30 days after the discontinuation of the IMP. Adequate contraceptive methods include combined hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal), progestogen-only hormonal contraception with inhibition of ovulation (oral, injectable, implantable), intrauterine devices (IUDs), intrauterine hormone-releasing system (IUS), true sexual abstinence (when this is in line with the preferred and usual lifestyle of the participant), bilateral tubal occlusion, vasectomized male partner or a female participant who is not of childbearing potential., Female participants and female partners of male study participants using a hormonal contraceptive must also use a barrier method (i.e., condom or occlusive cap [diaphragm or cervical/vault caps]) and should have been stable on their hormonal contraceptive treatment for at least 4 weeks prior to Screening; Sexually active male subjects must use a highly effective method of contraception during the study and agree to continue the use of highly effective contraception for at least 30 days after the last dose of study drug; If <18 years of age, both of the subject’s parents or legal guardian, based on country and/or local laws, must sign a written informed consent and subject must sign a written informed assent according to the requirements of the site’s IRB/EC. If =18 years of age, subjects must sign a written informed consent according to the requirements of the site’s IRB/EC: Subjects must have TD based on Diagnostic and Statistical Manual for Mental Disorders – 5th Edition (DSM-5-TR diagnostic criteria) for TD; Subjects must exhibit both motor and vocal tics that cause impairment with normal routines.
排除标准
- •Any subject who was either lost to follow up, withdrawn consent, is non-compliant with study procedures, or study drug or otherwise withdrawn by either the site investigator or the sponsor at their discretion from PSY-302A, EBS-101-OL-001 or EBS-101-TD-301 studies; Subjects with a clinical presentation and/or history consistent with another neurologic condition that may have had accompanying abnormal movements (e.g., Huntington’s disease, Parkinson’s disease, Wilson’s disease, stroke, Restless Legs Syndrome); Any unstable mood disorder (DSM-5-TR criteria) at time of Screening or Baseline; Subjects who have unstable medical illness or clinically significant abnormalities on laboratory tests or ECG at Screening or Baseline as determined by the Principal Investigator. Subjects who have moderate to severe renal impairment at Screening; Subjects who have hepatic impairment at Screening; Adult subjects with PHQ-9 score > 10 at Screening or Baseline; Subjects with a history of neuroleptic malignant syndrome;, Subjects who have had previous treatment with investigational medication within 4 weeks prior to Screening for subjects who completed studies EBS-101-OL-001 or PSY-302A; Oral neuroleptics within 4 weeks prior to Screening; depot neuroleptics within 3 months prior to Baseline (e.g., risperidone microspheres) or 6 months prior to Baseline (e.g., paliperidone palmitate) for those subjects who completed EBS-101-OL-001 and PSY-302A; Subjects receiving other medications to treat motor or vocal tics except for baclofen, botulinum toxin, clonazepam, guanfacine, and topiramate would need those discontinued for at least 14 days prior to Baseline; Subjects receiving anti-depressant, anti-anxiety or ADHD medications unless the dosage has been stable for a minimum of 4 weeks prior to Baseline, unless otherwise excluded; Subjects who have required deep brain stimulation treatment ; Subjects with an onset of a major depressive episode in the past 6 months; Subject with a significant risk of attempting suicide based on history (suicide attempt in past 1 year or who have had 2 or more lifetime suicide attempts), or who had an answer of ‘‘yes’’ to either questions 4 or 5 (currently or within the past 30 days) on the baseline/screening version of the C-SSRS; Subjects with a history of seizures (excluding febrile seizures that occurred > 2 years prior to Baseline);, Subjects with a myocardial infarction within 6 months from Screening; Female subjects who are currently pregnant or lactating or planning to become pregnant during the course of the study; Subjects who have a need for medications which would have unfavorable interactions with ecopipam, e.g., CYP2D6 substrates with a narrow therapeutic window (e.g., digoxin), and drug with similar mechanism of action to ecopipam such as dopamine antagonists (e.g. neuroleptics), and VMAT2 inhibitors (e.g. tetrabenazine). Refer to Section 22 and 23 for allowable and prohibited medications; Subjects with current or recent (past 3 months) DSM-5 substance use disorder (with the exception of nicotine); Subjects with positive urine drug screen for cocaine, amphetamine, benzodiazepines, barbiturates, phencyclidine (PCP) or opiates at Baseline, except those receiving stable, prescribed treatment conditions unless specifically prohibited;, Subjects with a lifetime history of bipolar disorder type I or II, dementia, schizophrenia, or any other psychotic disorder; Subjects unable to swallow tablets; Subjects with a known hype
研究者
相似试验
进行中（未招募）
1 期
A Study with an active treatment to Assess the Long-term Safety of Weekly Intravenous Product in Subjects with Pulmonary Emphysema due to Alpha1-Antitrypsin DeficiencyEUCTR2015-004110-23-FIGrifols Therapeutics LLC250
进行中（未招募）
1 期
A Study with an active treatment to Assess the Long-term Safety of Weekly Intravenous Product in Subjects with Pulmonary Emphysema due to Alpha1-Antitrypsin DeficiencyPulmonary Emphysema due to Alpha-1-Antitrypsin DeficiencyMedDRA version: 20.0Level: LLTClassification code 10014563Term: Emphysema pulmonarySystem Organ Class: 100000004855EUCTR2015-004110-23-PLGrifols Therapeutics LLC250
进行中（未招募）
1 期
A Study with an active treatment to Assess the Long-term Safety of Weekly Intravenous Product in Subjects with Pulmonary Emphysema due to Alpha1-Antitrypsin DeficiencyPulmonary Emphysema due to Alpha-1-Antitrypsin DeficiencyMedDRA version: 20.0Level: LLTClassification code 10014563Term: Emphysema pulmonarySystem Organ Class: 100000004855EUCTR2015-004110-23-DKGrifols Therapeutics LLC250
进行中（未招募）
不适用
An Open Label, Multicenter Study to Evaluate the Long Term Safety of Prolonged Release (PR) OROS Methylphenidate (18, 36, 54, 72 and 90 mg/day) in Adults with Attention Deficit/Hyperactivity DisorderEUCTR2005-004037-18-PTJanssen-Cilag EMEA400
进行中（未招募）
1 期
An Open-label, Multicenter Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of AEB1102 in Patients with Arginase I DeficiencyEUCTR2018-003163-67-PTAeglea Biotherapeutics, Inc.14